Browsing by Author "Gabrawy, Mariann M."
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Dual treatment with kynurenine pathway inhibitors and NAD⁺ precursors synergistically extends life span in Drosophila(Wiley, 2024-03-13) Gabrawy, Mariann M.; Westbrook, Reyhan; King, Austin; Khosravian, Nick; Ochaney, Neeraj; DeCarvalho, Tagide; Wang, Qinchuan; Yu, Yuqiong; Huang, Qiao; Said, Adam; Abadir, Michael; Zhang, Cissy; Khare, Pratik; Fairman, Jennifer E.; Le, Anne; Milne, Ginger L.; Vonhoff, Fernando J; Walston, Jeremy D.; Abadir, Peter M.Tryptophan catabolism is highly conserved and generates important bioactive metabolites, including kynurenines, and in some animals, NAD⁺. Aging and inflammation are associated with increased levels of kynurenine pathway (KP) metabolites and depleted NAD⁺, factors which are implicated as contributors to frailty and morbidity. Contrastingly, KP suppression and NAD⁺ supplementation are associated with increased life span in some animals. Here, we used DGRP_229 Drosophila to elucidate the effects of KP elevation, KP suppression, and NAD⁺ supplementation on physical performance and survivorship. Flies were chronically fed kynurenines, KP inhibitors, NAD⁺ precursors, or a combination of KP inhibitors with NAD⁺ precursors. Flies with elevated kynurenines had reduced climbing speed, endurance, and life span. Treatment with a combination of KP inhibitors and NAD⁺ precursors preserved physical function and synergistically increased maximum life span. We conclude that KP flux can regulate health span and life span in Drosophila and that targeting KP and NAD⁺ metabolism can synergistically increase life span.Item Genome-Wide Analysis in Drosophila Reveals the Genetic Basis of Variation in Age-Specific Physical Performance and Response to ACE Inhibition(MDPI, 2022-01-14) Gabrawy, Mariann M.; Khosravian, Nick; Morcos, George S.; Morozova, Tatiana V.; Jezek, Meagan; Walston, Jeremy D.; Huang, Wen; Abadir, Peter M.; Leips, JeffDespite impressive results in restoring physical performance in rodent models, treatment with renin–angiotensin system (RAS) inhibitors, such as Lisinopril, have highly mixed results in humans, likely, in part, due to genetic variation in human populations. To date, the genetic determinants of responses to drugs, such as RAS inhibitors, remain unknown. Given the complexity of the relationship between physical traits and genetic background, genomic studies which predict genotype- and age-specific responses to drug treatments in humans or vertebrate animals are difficult. Here, using 126 genetically distinct lines of Drosophila melanogaster, we tested the effects of Lisinopril on age-specific climbing speed and endurance. Our data show that functional response and sensitivity to Lisinopril treatment ranges from significant protection against physical decline to increased weakness depending on genotype and age. Furthermore, genome-wide analyses led to identification of evolutionarily conserved genes in the WNT signaling pathway as being significantly associated with variations in physical performance traits and sensitivity to Lisinopril treatment. Genetic knockdown of genes in the WNT signaling pathway, Axin, frizzled, nemo, and wingless, diminished or abolished the effects of Lisinopril treatment on climbing speed traits. Our results implicate these genes as contributors to the genotype- and age-specific effects of Lisinopril treatment and because they have orthologs in humans, they are potential therapeutic targets for improvement of resiliency. Our approach should be widely applicable for identifying genomic variants that predict age- and sex-dependent responses to any type of pharmaceutical treatment.Item Lisinopril preserves physical resilience and extends life span in a genotype-specific manner in Drosophila melanogaster(Oxford University Press, 2019-06-14) Gabrawy, Mariann M.; Campbell, Sarah; Carbone, Mary Anna; Morozova, Tatiana V.; Arya, Gunjan H.; Turlapati, Lavanya B.; Walston, Jeremy D.; Starz-Gaiano, Michelle; Everett, Logan; Mackay, Trudy F. C.; Leips, Jeff; Abadir, Peter M.Physical resiliency declines with age and comorbid conditions. In humans, Angiotensin Converting Enzyme (ACE) has been associated with attenuation of the decline in physical performance with age. ACE-inhibitor (ACEi) compounds, commonly prescribed for hypertension, often have beneficial effects on physical performance however the generality of these effects are unclear. Here, we tested the effects of the ACE-inhibitor Lisinopril on life span, and age-specific speed, endurance, and strength using three genotypes of the D. melanogaster Genetic Reference Panel. We show that age-related decline in physical performance and survivorship varies with genetic background. Lisinopril treatment increased mean life span in all DGRP lines, but its effects on lifespan, speed, endurance, and strength depended on genotype. We show that genotypes with increased physical performance on Lisinopril treatment experienced reduced age-related protein aggregation in muscle. Knockdown of skeletal musclespecific Ance, the Drosophila ortholog of ACE, abolished the effects of Lisinopril on lifespan, implying a role for skeletal muscle Ance in survivorship. Using transcriptome profiling, we identified genes involved in stress response that showed expression changes associated with genotype and age-dependent responsiveness to Lisinopril. Our results demonstrate that Ance is involved in physical decline and demonstrate genetic variation in phenotypic responses to an ACE inhibitor.